Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorQianfoshan Hospital
About this trial
The objective of this study is to investigate the efficacy and safety of urapidil monotherapy versus the combination of esmolol in treating participants with acute hypertensive intracerebral hemorrhage through a prospective, open-label, observational, multicenter clinical trial, aiming to provide guidance for clinicians in formulating rational treatment plans.
Eligibility criteria
Qualifiers
Participants in the study of acute hypertensive intracerebral hemorrhage aged between 18 and 80 years old;
Participants with acute intracerebral hemorrhage (basal ganglia hemorrhage < 50ml) confirmed by imaging within 6 hours of onset;
Participants with systolic blood pressure > 140mmHg upon admission;
Participants who have signed the informed consent form.
Disqualifiers
Participants in the cerebral hemorrhage study who decline to have their disease management information collected and used and/or refuse to undergo subsequent follow-ups;
Participants with allergies to the medication in question;
Participants in the study of secondary cerebral hemorrhage resulting from tumors, vascular malformations, aneurysms, trauma, post-thrombolytic therapy, or cerebral arteriovenous thrombosis;
Participants undergoing anticoagulant therapy or with coagulation disorders;
Trial design
Treatments tested in this trial
- Urapidil
- Urapidil and Esmolol
Treatment groups
600 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov